rs2307449 — POLG
Intronic variant in POLG (mitochondrial DNA polymerase gamma) on chromosome 15q26.1; the G allele is associated with earlier natural menopause by approximately 9–10 weeks per allele, implicated through mitochondrial DNA replication fidelity and oocyte energy metabolism
Details
- Gene
- POLG
- Chromosome
- 15
- Risk allele
- G
- Clinical
- Risk Factor
- Evidence
- Strong
Population Frequency
Category
Gamete Quality & DNA RepairSee your personal result for POLG
Upload your DNA data to find out which genotype you carry and what it means for you.
Upload your DNA dataWorks with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.
POLG — When Mitochondrial DNA Polymerase Shapes the Timing of Menopause
Every cell in the body contains hundreds to thousands of mitochondria, each carrying its own
small circle of DNA — the mitochondrial genome11 mitochondrial genome
16,569 base pairs encoding 37 genes, all
essential for the electron transport chain that generates ATP.
Unlike nuclear DNA, which is replicated by a team of polymerases with redundant error-checking,
mitochondrial DNA relies on a single enzyme for both replication and repair: POLG22 POLG
DNA
polymerase gamma, the catalytic subunit encoded by POLG on chromosome 15q26.1; the only
mitochondrial DNA polymerase in humans. A common intronic
variant in POLG — rs2307449 — has emerged from large-scale genome-wide data as a modulator
of when women reach natural menopause, connecting the fidelity of mitochondrial DNA replication
to the biological clock of the ovary.
The Mechanism
Why would a variant near POLG affect menopause timing? The answer lies in the extraordinary
mitochondrial demands of oocytes. A mature human oocyte contains approximately
100,000–500,000 copies of mtDNA33 100,000–500,000 copies of mtDNA
far more than any somatic cell; this massive mtDNA
stockpile must be assembled during oocyte growth and is the sole mitochondrial inheritance
passed to the embryo. Maintaining the fidelity
of this mitochondrial genome throughout the decades of female reproductive life requires
continuous mtDNA replication and repair — a task that falls entirely to POLG and its accessory
subunit POLG2.
When POLG fidelity is subtly compromised — as accumulated mtDNA mutations in oocytes and
granulosa cells increase — the consequences for reproductive capacity are substantial.
Studies in POLG mutator mice44 Studies in POLG mutator mice
Yang et al. 2020, Aging Cell — mtDNA mutations impair oocyte
NADH/NAD+ redox, reducing ovarian primordial and mature follicles; NMN supplementation
partially rescues fertility demonstrated that
mtDNA mutation accumulation reduces ovarian follicle counts, specifically by impairing the
oocyte's NADH/NAD+ redox balance55 NADH/NAD+ redox balance
the ratio of reduced to oxidised nicotinamide adenine
dinucleotide; central to mitochondrial energy production; disrupted when the electron
transport chain is compromised by mtDNA mutations.
A second mouse study found that POLG mutations caused profound meiotic spindle defects and
chromosome misalignment in oocytes — defects that calorie restriction, which rescues age-related
fertility in normal mice, could not reverse66 could not reverse
Faraci et al. 2018, PLoS One — POLG mutator
mice develop mtDNA-integrity–specific oocyte defects distinct from normal reproductive aging
defects. This suggests that mtDNA integrity
failure is a mechanistically distinct cause of ovarian aging.
The intronic position of rs2307449 (c.2981+69 in the POLG transcript) means it does not alter the amino acid sequence of the POLG protein. Instead, it likely acts as a regulatory variant — potentially affecting POLG transcript levels, splicing efficiency, or mRNA stability in ovarian tissue — subtly modulating the cumulative fidelity of mtDNA replication across the reproductive lifespan.
The Evidence
The key human evidence comes from the largest GWAS meta-analysis of age at natural menopause
conducted at the time:
Stolk et al. 201277 Stolk et al. 2012
Meta-analyses identify 13 loci associated with age at menopause and
highlight DNA repair and immune pathways. Nature Genetics, 2012.
The study combined data from 22 genome-wide association studies encompassing 38,968 women of
European ancestry, with replication in up to 14,435 additional women. At the POLG locus
(chromosome 15), rs2307449 reached a combined p-value of 3.56×10⁻¹³ and an effect size of
−0.184 years per G allele — approximately 9–10 weeks earlier menopause per copy of G. The
association was genome-wide significant (p=2.59×10⁻⁸) in the discovery stage alone.
Beyond POLG, the same study found that the newly identified menopause loci were enriched for DNA repair and mitochondrial dysfunction pathways — a convergence pointing to ovarian DNA integrity as a central clock mechanism for the reproductive lifespan. POLG's co-identification alongside EXO1, HELQ, FANCI, and BRCA2-pathway genes in this analysis reinforces its role as a DNA maintenance gene whose fidelity limits how long the ovary can sustain a functional primordial follicle pool.
A clinical letter by
Duncan et al. 201288 Duncan et al. 2012
POLG mutations and age at menopause. Human Reproduction, 2012
extended these findings by reporting POLG mutations directly associated with altered menopause
age in clinical cohorts, bridging the rare-disease genetics of POLG (where pathogenic
mutations cause Alpers syndrome, progressive external ophthalmoplegia, and other severe
mitochondrial diseases) to the common-variant GWAS signal.
Practical Actions
For women carrying the G allele — particularly GG homozygotes — the clearest actionable implication is awareness of potentially earlier natural menopause. This has downstream consequences for fertility planning, hormone therapy decisions, and bone health monitoring. Ovarian reserve testing (AMH, antral follicle count) provides a direct readout of remaining follicle pool, and earlier testing is warranted when POLG risk alleles are present.
At the mitochondrial level, maintaining oocyte NAD+ availability is the experimentally supported intervention. NMN (nicotinamide mononucleotide) supplementation rescued impaired oocyte redox balance and partially restored fertility in POLG mutator mice in the Yang 2020 study. NMN is an NAD+ precursor — it replenishes the NAD+ pool that mtDNA-damaged oocytes struggle to maintain. Human trials of NMN for ovarian aging are ongoing as of 2024.
CoQ10 (as ubiquinol) supports mitochondrial electron transport chain efficiency and has been studied specifically in the context of oocyte quality for IVF, where mitochondrial function is a key determinant of embryo development potential.
Interactions
rs2307449 in POLG belongs to a cluster of DNA repair and mitochondrial maintenance genes that the Stolk 2012 meta-analysis identified as collectively influencing menopause timing. In the GeneOps fertility-reproductive category, several related variants share the DNA repair theme: rs1635501 (EXO1, exonuclease for DNA repair), rs2747648 (ESR1, estrogen receptor regulatory ovarian failure), and rs11140679 (BRCA2, homologous recombination). Women carrying risk alleles at multiple DNA repair loci may have a compounded effect on ovarian aging, though combined-locus data are not yet available from GWAS.
Genotype Interpretations
What each possible genotype means for this variant:
Common genotype — typical mitochondrial DNA polymerase function
You carry the T/T genotype at rs2307449 in POLG. The T allele is the GRCh38 reference and the population-major allele globally (~60%), associated with typical POLG function and normal-range menopause timing. About 36% of women share this genotype. No specific action is indicated at this locus.
One copy of the earlier-menopause allele — modestly earlier reproductive lifespan
The POLG intronic variant rs2307449 was identified as a genome-wide significant locus for age at natural menopause (Stolk et al. 2012, Nat Genet; combined p=3.56×10⁻¹³). The G allele shifts menopause earlier by approximately −0.184 years per copy. For GT heterozygotes, this translates to approximately 9–10 weeks earlier than the TT baseline on average. The biological mechanism connects POLG-mediated mitochondrial DNA replication fidelity to ovarian follicle survival: even subtle reductions in POLG function can accelerate mtDNA mutation accumulation in oocytes over decades, progressively impairing oocyte energetics and triggering follicle apoptosis.
The MAF of G is ~39% in Europeans and ~40% globally, making this a common variant with modest individual effect. Its clinical relevance is primarily in contextualising fertility planning windows and informing proactive ovarian reserve assessment.
Two copies of the earlier-menopause allele — meaningfully earlier expected reproductive lifespan
The GG genotype carries the maximum POLG locus loading for earlier menopause. With two copies of the G allele, the expected shift is approximately 2 × (−0.184 years) = −0.37 years, or roughly 4–5 months earlier than the TT baseline on the population average. Combined with other DNA repair loci (EXO1, MCM8, BRCA2 variants), the cumulative shift could be substantially larger. The Stolk 2012 meta-analysis showed that POLG is part of a broader set of DNA repair and mitochondrial maintenance genes that collectively explain a significant portion of the heritability of menopause timing.
Mechanistic mouse data (Yang et al. 2020, Aging Cell) demonstrated that accumulated mtDNA mutations impair oocyte NADH/NAD+ redox balance, reduce follicle counts, and cause female-specific infertility — effects that were partially rescued by nicotinamide mononucleotide (NMN) supplementation. While direct human trial data for NMN in POLG-variant carriers are not yet available, the mechanistic rationale is the strongest available for any supplement in this context.
From a clinical management perspective, the GG genotype justifies proactive and repeated ovarian reserve monitoring, ideally starting in the late 20s. AMH provides a direct numerical readout of remaining primordial follicle pool; declining AMH trajectories are more informative than any single measurement. Bone density monitoring from early perimenopause (or by age 45) is warranted, since earlier oestrogen withdrawal accelerates early bone loss.